Search Results
Your search for 3 matches 15507 pages
Showing 14501 - 14550ASCO 2015: IMGN853 Demonstrates Single-Agent Activity for Patients With Platinum-Resistant Ovarian Cancer
In a phase I trial, the investigational agent mirvetuximab soravtansine (IMGN853) was found to be active in patients with platinum-resistant ovarian cancer. ImmunoGen, Inc, announced the first clinical findings of this folate-receptor alpha (FRα)-targeting antibody-drug conjugate at the...
HPV Serum Antibodies May Predict Survival and Disease Progression in Patients With HPV-Positive Oropharyngeal Cancer
A study by Dahlstrom et al investigating the usefulness of serum antibodies to human papillomavirus (HPV)-16 DNA antigens as predictors of survival for patients with oropharyngeal carcinoma has found that E1, NE2, and E6 antibody positivity were all strongly associated with improved overall and...
French Trial Shows Addition of Docetaxel and Estramustine to ADT Improves Relapse-Free Survival in High-Risk Localized Prostate Cancer
In a French phase III trial (GETUG 12) reported in The Lancet Oncology, Fizazi et al found that the addition of docetaxel and estramustine (Emcyt) to androgen-deprivation therapy (ADT) improved relapse-free survival among patients with high-risk localized prostate cancer. Study Details In the...
New Molecular Diagnostic Test Predicts Progression of Barrett's Esophagus to Esophageal Cancer
Interpace Diagnostics, a subsidiary of PDI, Inc, announced new data demonstrating the clinical value of BarreGen, a molecular diagnostic test that predicts the risk of progression from Barrett’s esophagus to esophageal cancer approximately 3 to 4 years before the cancer develops. These...
Palbociclib Improves Progression-Free Survival in Advanced Hormone Receptor–Positive Breast Cancer
In a phase III PALOMA 3 trial reported at the 2015 ASCO Annual Meeting and published in The New England Journal of Medicine, Turner et al found that the cyclin-dependent kinase 4 and 6 inhibitor palbociclib (Ibrance) significantly improved progression-free survival in women with advanced hormone...
Pooled Analysis Shows Activity of Afatinib Differs in NSCLC According to Uncommon EGFR Mutations
In a pooled analysis of the LUX-Lung 2, 3, and 6 trials reported in The Lancet Oncology, Yang et al found that the activity of afatinib (Gilotrif) differed according to uncommon EGFR mutations in advanced non–small cell lung cancer (NSCLC). Most patients with EGFR-mutant NSCLC have deletion...
Addition of Elotuzumab to Lenalidomide-Dexamethasone Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma
In an interim analysis of the phase III ELOQUENT-2 trial reported in The New England Journal of Medicine, Lonial et al found that the addition of the investigational agent elotuzumab to lenalidomide (Revlimid)-dexamethasone significantly increased progression-free survival in patients with relapsed ...
Latest RTOG 0537 Data Indicate Electrical Nerve Stimulation May Provide Relief for Radiation-Induced Dry Mouth
Phase III results of Radiation Therapy Oncology Group (RTOG) 0537 indicate that acupuncture-like, transcutaneous electrical nerve stimulation (ALTENS) may be equally effective as the prescription medication pilocarpine, the current standard of care, to treat radiation-induced xerostomia (dry...
Addition of Necitumumab to First-Line Gemcitabine-Cisplatin Improves Overall Survival in Stage IV Squamous NSCLC
In the phase III SQUIRE trial reported in The Lancet Oncology, Thatcher et al found that the addition of the second-generation epidermal growth factor receptor (EGFR) antibody necitumumab to first-line gemcitabine-cisplatin improved overall survival among patients with stage IV squamous...
Bronchial Gene-Expression Classifier Improves Bronchoscopy Performance in Diagnosing Lung Cancer
In a study reported in The New England Journal of Medicine, Silvestri et al of the AEGIS study team found that use of a bronchial airway gene-expression classifier improved the diagnostic performance of bronchoscopy in patients being evaluated for suspected lung cancer. Study Details The study...
ASCO 2015: New Targeted Treatment IMMU-130 Shows Activity in Patients With Metastatic Colon Cancer
Although various drugs have improved outcomes for metastatic colon cancer patients, researchers continually strive to find new agents to improve treatment. Antibody-drug conjugates are a promising option, due to the fact that they can deliver chemotherapy directly into a targeted cell, destroy...
Higher Tumor-Infiltrating Lymphocyte Level Associated With Better Outcomes in HER2-Positive Early Breast Cancer Independent of Neoadjuvant Treatment
In an analysis of the NeoALTTO trial reported in JAMA Oncology, Salgado et al found that a higher level of tumor-infiltrating lymphocytes was associated with improved pathologic compete response rate and event-free survival independent of neoadjuvant treatment received in patients with...
Phase III Trial Confirms Benefit of Adding Bevacizumab to Chemotherapy in Chinese Patients With Advanced NSCLC
In a phase III BEYOND trial reported in the Journal of Clinical Oncology, Zhou et al found that the addition of bevacizumab to carboplatin-paclitaxel improved progression-free and overall survival in Chinese patients with locally advanced, metastatic, or recurrent advanced nonsquamous...
ASCO 2015: Novel Targeted Drug Palbociclib Slows Progression of Hormone Receptor–Positive Breast Cancer
Results from the phase III registration study PALOMA-3 show that adding the investigational targeted agent palbociclib (Ibrance) to the standard hormonal therapy fulvestrant (Faslodex) more than doubled the duration of disease control, delaying disease progression by roughly 5 months in women with...
ASCO 2015: Anastrozole Offers Higher Breast Cancer–Free Interval Rates Than Tamoxifen Following Lumpectomy and Radiation for DCIS
A phase III trial comparing 5 years of tamoxifen vs 5 years of the aromatase inhibitor anastrozole for postmenopausal women treated for ductal carcinoma in situ (DCIS) found 10-year breast cancer–free interval rates were higher in the anastrozole group than in the tamoxifen group (93.5% vs...
ASCO 2015: Entolimod May Be a Promising Treatment Option for Many Solid Tumors
A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute, shared results from the first clinical study of the anticancer effects of the novel agent entolimod on May 30 at the 2015 ASCO Annual Meeting in Chicago (Abstract 3063). Their findings confirm ...
ASCO 2015: Economic Costs a Burden for Cancer Survivors
A new study conducted by the American Cancer Society found that the economic burden of cancer extends beyond diagnosis and treatment, with cancer survivors facing thousands of dollars of excess medical expenses every year, as well as excess employment disability and loss of production at work. The...
Oncolytic Immunotherapy With Talimogene Laherparepvec Improves Durable Response Rate in Advanced Melanoma
In a phase III trial reported in the Journal of Clinical Oncology, Andtbacka et al found that talimogene laherparepvec (T-VEC) treatment improved the durable response rate vs granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with unresectable stage IIIB to IV melanoma. T-VEC is...
ASCO 2015: Eribulin Extends Overall Survival for Heavily Pretreated Patients With Advanced Liposarcoma and Leiomyosarcoma
Heavily pretreated patients with intermediate- or high-grade liposarcoma or leiomyosarcoma had a 2-month increase in median overall survival when subsequently treated with eribulin (Halaven) rather than the standard drug dacarbazine. “For a disease where so few treatment options exist, a...
Adjuvant Regimen Produces Good Survival Results in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
In a phase II Intergroup study (SWOG S0809) reported in the Journal of Clinical Oncology, Ben-Josef et al found that adjuvant capecitabine and gemcitabine followed by concurrent radiotherapy and capecitabine produced good survival results in patients with extrahepatic cholangiocarcinoma or...
ASCO 2015: Investigational ALK Inhibitor Demonstrates Promising Overall Response Rates in Patients With Advanced ALK-Positive NSCLC
The oral investigational anaplastic lymphoma kinase (ALK) inhibitor alectinib shrank tumors in almost half of patients with advanced ALK-positive non–small cell lung cancer (NSCLC) whose disease had progressed following crizotinib (Xalkori) treatment. Positive results from two clinical...
ASCO 2015: Complete Lymph Node Dissection Does Not Improve Survival in Patients With Melanoma and Micrometastases
For patients with melanoma and micrometastases, as shown by positive sentinel lymph node biopsy, complete lymph node dissection did not improve survival, according to results of a randomized study presented at the 2015 ASCO Annual Meeting (Abstract LBA9002). “This is the first study which...
ASCO 2015: For Patients With Limited Brain Metastases, Adjuvant Whole-Brain Radiation Therapy Increases Cognitive Decline Without Improving Survival
A federally funded phase III trial found that adding whole-brain radiation therapy to radiosurgery did not significantly extend survival of patients with one to three small metastases of the brain, although it did help to control the growth of brain metastases, as evidenced by imaging studies....
ASCO 2015: Reduction in Late Mortality Among Childhood Cancer Survivors Linked to Improvements in Cancer Care
Survivors of childhood cancer in recent eras have shown a significant reduction in late mortality, and “for the first time, we have been able to attribute that to fewer deaths from treatment-related causes or fewer deaths from late effects of the primary therapy,” Gregory T....
ASCO 2015: Second-Line Afatinib Improves Overall Survival vs Erlotinib in Advanced Squamous Cell Carcinoma of the Lung
In a phase III head-to-head trial comparing the safety and efficacy of two EGFR-directed treatments, afatinib (Gilotrif) treatment resulted in a significant improvement in overall survival over erlotinib (Tarceva) in patients with previously treated advanced squamous cell carcinoma of the lung....
ASCO 2015: Phase III Study Finds Nivolumab Improves Progression-Free Survival, Especially When Combined With Ipilimumab, in Advanced Melanoma
A randomized phase III trial among patients with previously untreated melanoma found that initial therapy with nivolumab (Opdivo) alone more than doubled the median progression-free survival compared with ipilimumab (Yervoy) alone (6.9 vs 2.9 months), and the benefit was even greater when the two...
ASCO 2015: Variations in Liver Cancer Attributable to Hepatitis Virus Variations
Significant clinical variations exist among patients with the most common type of liver cancer, hepatocellular carcinoma, depending on the viral cause of the disease—hepatitis B virus (HBV) or hepatitis C virus (HCV). These differences suggest that hepatitis status should be considered when...
ASCO 2015: Pembrolizumab Produces Clinically Meaningful Response in Patients With Recurrent or Metastatic Head and Neck Cancer
Immunotherapy with pembrolizumab (Keytruda) produced a clinically meaningful overall response rate in a study among 132 patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The overall objective response rate was 24.8%, and 57% of patients experienced some tumor...
ASCO 2015: Nivolumab Extends Survival for Patients With Nonsquamous Non–Small Cell Lung Cancer
Superior overall survival was experienced by patients receiving the anti–PD-1 antibody nivolumab (Opdivo) in a randomized phase III study of patients with nonsquamous non–small cell lung cancer (NSCLC) whose disease progressed after a platinum-based doublet chemotherapy. Study...
Vismodegib Safety Profile in Long-Term ‘Real-World’ Use in Advanced Basal Cell Carcinoma
In a preplanned interim analysis of the international open-label STEVIE trial reported in The Lancet Oncology, Basset-Seguin et al have provided safety data and efficacy outcomes with the use of vismodegib (Erivedge) for 1 year in patients with advanced basal cell carcinoma. STEVIE was designed to...
Minority of Medicare Patients Have Adequate Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy for Breast Cancer
In a study reported in the Journal of Clinical Oncology, Chavez-MacGregor et al found that the majority of older breast cancer patients receiving trastuzumab (Herceptin)-based chemotherapy do not receive adequate cardiac monitoring. Study Details The study involved 2,203 patients aged ≥...
UK Trial Shows Neoadjuvant Platinum-Based Chemotherapy Noninferior to Adjuvant Chemotherapy in Advanced Ovarian Cancer
In the UK phase III CHORUS trial reported in The Lancet, Kehoe et al found that a strategy of three cycles of platinum-based chemotherapy followed by delayed surgery and three additional cycles of chemotherapy was associated with overall survival noninferior to that achieved with surgery followed...
Second-Line Dovitinib Shows Some Activity in FGFR2-Mutant and FGFR2-Nonmutant Advanced Endometrial Cancer
In a phase II study reported in The Lancet Oncology, Konecny et al found that the multi–tyrosine kinase inhibitor dovitinib appeared to delay progression in some patients as second-line treatment in fibroblast growth factor receptor 2 (FGFR2)-mutant and -nonmutant advanced or metastatic...
Regorafenib Improves Overall Survival in Asian Patients With Previously Treated Metastatic Colorectal Cancer
In the phase III CONCUR trial reported in The Lancet Oncology, Li et al found that the multikinase inhibitor regorafenib (Stivarga) improved overall survival vs placebo in Asian patients with previously treated metastatic colorectal cancer. Regorafenib has been approved by the U.S. Food and Drug...
Hedgehog Inhibitor Sonidegib Active in Advanced Basal Cell Carcinoma
In the phase II BOLT trial reported in The Lancet Oncology, Migden et al found that the hedgehog pathway signaling inhibitor sonidegib produced responses in patients with locally advanced or metastatic basal cell carcinoma at 200-mg and 800-mg dose levels. The lower dose appeared to be associated...
Multimodal Therapy Benefits Men With Prostate Cancer Experiencing Biochemical Recurrence After Local Therapy
In men who experience biochemical disease recurrence after local therapy for prostate cancer, docetaxel, bevacizumab (Avastin), and androgen-deprivation therapy may be beneficial, according to a study by McKay et al in Cancer. Further evaluation of this combination treatment is warranted to...
First-in-Class Antibody Mixture Shows Clinical Activity Against Treatment-Resistant, Advanced Colorectal Cancer
Patients with advanced colorectal tumors without mutations in the RAS genes derive substantial benefit from anti-EGFR (epidermal growth factor receptor) therapies; however, the disease eventually progresses, leaving these patients with few alternative therapeutic options. Over the past decade, some ...
Pazopanib Plus Octreotide Active in Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
In a phase II study reported in The Lancet Oncology, Phan et al found that the VEGFR-1, -2, -3 inhibitor pazopanib (Votrient) plus depot octreotide produced responses in patients with advanced well-differentiated neuroendocrine tumors. No responses were observed in patients with carcinoid tumors....
More Than One-Third of Patients Diagnosed With Hepatocellular Carcinoma as Outpatients Have Diagnostic Delays
Nearly 20% of patients with hepatocellular carcinoma “wait more than 3 months from presentation to diagnosis, which can contribute to interval tumor growth,” Patel et al concluded in the Journal of the National Comprehensive Cancer Network. They based their conclusions on a review of...
Omega-3 Fatty Acids and Placebo Reduce Aromatase Inhibitor–Related Musculoskeletal Pain in Early Breast Cancer
In the SWOG S0927 trial reported in the Journal of Clinical Oncology, Hershman et al found that both omega-3 fatty acids and placebo resulted in marked persistent reductions in aromatase inhibitor–related arthralgia among patients with early breast cancer, with no difference between...
German Trial Shows Reduced Risk of Venous Thromboembolism With Prophylactic Enoxaparin in Ambulatory Patients With Advanced Pancreatic Cancer
In the German CONKO-004 trial reported in the Journal of Clinical Oncology, Pelzer et al found that prophylactic treatment with the low-molecular-weight heparin enoxaparin reduced the risk of symptomatic venous thromboembolic events in ambulatory patients receiving first-line chemotherapy for...
Improved Pathologic Complete Response Rate With Addition of Bevacizumab to Neoadjuvant Therapy in HER2-Negative Early Breast Cancer
In the phase III ARTemis trial reported in The Lancet Oncology, Earl et al found that the addition of bevacizumab (Avastin) to standard neoadjuvant therapy resulted in a higher pathologic complete response rate in women with HER2-negative early breast cancer. Study Details In this open-label...
Stereotactic Ablative Radiotherapy Achieves Better Overall Survival Than Surgery in Stage I NSCLC
Patients with operable stage I non–small cell lung cancer (NSCLC) could achieve better overall survival rates if treated with stereotactic ablative radiotherapy rather than the invasive surgery, the current standard of care, according to research from a phase III randomized international...
Physical Activity Programs Produce Benefits in Patients Receiving Adjuvant Therapy for Breast Cancer
In the Dutch PACES trial reported in the Journal of Clinical Oncology, van Waart et al found that both a moderate/high-intensity supervised exercise program and a low-intensity home-based program provided benefits vs usual care in women undergoing adjuvant chemotherapy for breast cancer. Benefits,...
American College of Physicians Offers Advice on High-Value Screening in Five Cancers
To provide guidance on high-value cancer care screening strategies, the American College of Physicians (ACP) recently reviewed clinical guidelines issued by various medical organizations for screening strategies in five common cancers for asymptomatic, average-risk adults. The five cancers focused...
Germline BRCA Mutations Found in Almost 5% of Patients With Pancreatic Adenocarcinoma
In a study reported in the Journal of Clinical Oncology, Holter et al found that 4.6% of a large clinic population of patients with pancreatic adenocarcinoma harbored pathogenic germline BRCA mutations. The study involved analysis of 306 unselected, consecutive, incident patients with pancreatic...
Combining Ixabepilone and Bevacizumab Appears Safe and Effective in Recurrent Uterine and Ovarian Cancers
In patients with recurrent/persistent uterine or ovarian/primary peritoneal/fallopian tube cancers, ixabepilone (Ixempra), especially with the addition of biweekly bevacizumab (Avastin), appears to be safe and effective, according to a study by Roque et al in Gynecologic Oncology. Further...
ASCO 2015: Adding Chemotherapy to Initial Therapy Improves Survival in Patients With Advanced, Hormone-Naive Prostate Cancer
The UK-led STAMPEDE trial found that adding docetaxel chemotherapy to standard hormone therapy markedly improved survival for men with newly diagnosed advanced prostate cancer not previously treated with hormone therapy (hormone-naive). Men who received docetaxel plus standard therapy lived on...
ASCO 2015: Oral Vitamin Reduces Risk of Common Nonmelanoma Skin Cancers in High-Risk Patients
The Australian ONTRAC trial showed that a form of vitamin B3 called nicotinamide significantly reduced the rates of new skin cancers in people at high risk of the disease. Taken as a twice-daily pill, nicotinamide reduced the incidence of new nonmelanoma skin cancers by 23%. These findings were...
No Significant Difference in Outcome for ABVD Plus Radiotherapy vs Stanford V in Stage I or II Bulky Mediastinal Hodgkin Lymphoma
As reported in the Journal of Clinical Oncology by Advani et al, a subset analysis of the phase III North American Intergroup E2496 trial showed no significant difference in failure-free or overall survival between ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) plus radiotherapy vs the...
